PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) has received a facsimile letter from Genentech (NYSE: DNA) asserting that Avastin®, Herceptin®, Lucentis® ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE